Literature DB >> 26978533

Paraoxonase 1 and 2 gene variants and the ischemic stroke risk in Gran Canaria population: an association study and meta-analysis.

Francisco Rodríguez-Esparragón1,2, Juan Carlos López-Fernández1,3,2, Nisa Buset-Ríos1, Miguel A García-Bello1, Erika Hernández-Velazquez1, Laura Cappiello1, José Carlos Rodríguez-Pérez1,3,2.   

Abstract

PURPOSE OF THE STUDY: The present study aims to evaluate the relationship between rs662 (Gln(Q)192Arg(R)) and rs854560 (L55M) and the rs7493 (S311C) in the paraoxonase genes and ischemic stroke (IS) in the population of Gran Canaria (Canary Islands). The association with stroke was also evaluated using systematic review and meta-analysis.
METHODS: A total of 129 IS patients and 176 age and gender matched controls were enrolled. For meta-analysis, eligible studies were identified through search in public databases.
RESULTS: In multivariate regression analysis only the PON2 S311C variant showed to be an independent predictor of IS (OR = 0.093, 95% CI: 0.014-0.627). Overall, no significant association was found between L55M and IS when all studies were pooled nor by subgroup analysis by ethnicity. Gln192Arg showed a modest risk for IS in the global and in Asian population but with high heterogeneity among studies. A modest risk under a dominant inheritance model was found for the S311C variant with an overall random effect OR of 1.004 (95% CI: 1.00-1.35). There was strong evidence of heterogeneity among studies (  p = 0.0097, I2 = 25.35%) which did not disappear after stratification by ethnicity.
CONCLUSIONS: The overall analysis shows a significant contribution of the rs662 variant to IS risk. We found that the CC genotype of the PON2 S311C polymorphism is a risk factor for IS. Results of the meta-analysis partially support this conclusion.

Entities:  

Keywords:  genetics; paraoxonase; polymorphisms; stroke

Mesh:

Substances:

Year:  2016        PMID: 26978533     DOI: 10.3109/00207454.2016.1165675

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Susceptibility of PON1/PON2 Genetic Variations to Ischemic Stroke Risk in a Chinese Han Population.

Authors:  Yuqin Pan; Bangshun He; Huiling Sun; Tao Xu; Bei Pan; Shukui Wang; Yanping Mei
Journal:  Pharmgenomics Pers Med       Date:  2020-10-29

2.  Association of PON2 Gene Polymorphisms (Ser311Cys and Ala148Gly) With the Risk of Developing Type 2 Diabetes Mellitus in the Chinese Population.

Authors:  Huan Ren; Sheng-Lan Tan; Mou-Ze Liu; Hoan L Banh; Jian-Quan Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-27       Impact factor: 5.555

Review 3.  Human Paraoxonase-2 (PON2): Protein Functions and Modulation.

Authors:  Giuseppe Manco; Elena Porzio; Teresa Maria Carusone
Journal:  Antioxidants (Basel)       Date:  2021-02-07

4.  Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.

Authors:  David Malicek; Ilka Wittig; Sebastian Luger; Christian Foerch
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

5.  PON1 (Paraoxonase 1) Q192R Gene Polymorphism in Ischemic Stroke among North Indian Population.

Authors:  Ankit Gupta; Alvee Saluja; Kallur Nava Saraswathy; Longkumer Imnameren; Suniti Yadav; Rajinder K Dhamija
Journal:  Ann Indian Acad Neurol       Date:  2021-10-22       Impact factor: 1.383

6.  Genomic Analyses of Human European Diversity at the Southwestern Edge: Isolation, African Influence and Disease Associations in the Canary Islands.

Authors:  Beatriz Guillen-Guio; Jose M Lorenzo-Salazar; Rafaela González-Montelongo; Ana Díaz-de Usera; Itahisa Marcelino-Rodríguez; Almudena Corrales; Antonio Cabrera de León; Santos Alonso; Carlos Flores
Journal:  Mol Biol Evol       Date:  2018-12-01       Impact factor: 16.240

7.  The Antioxidant Enzyme PON1: A Potential Prognostic Predictor of Acute Ischemic Stroke.

Authors:  Yuzhen Xu; Kai Wang; Qian Wang; Yihong Ma; Xueyuan Liu
Journal:  Oxid Med Cell Longev       Date:  2021-02-05       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.